Rate My Professor Martin Gagnon

Prior to his current appointments, Gagnon held the position of Chief Operating Officer at Exactis Innovation, overseeing a pan-Canadian clinical and molecular patient registry focused on cancer research. He co-founded Chlorion Pharma, a neuroscience biotechnology company, where he functioned as Chief Operating Officer and Vice President of Research, advancing innovative treatments for neuropathic pain and epilepsy. Over his career, he has secured more than $100 million in research financing. Gagnon's research specializations center on pharmacology and therapeutics, particularly mechanisms involving neuronal chloride extrusion and GABAA receptors in pain pathology. Key publications include "Enhancing neuronal chloride extrusion rescues α2/α3 GABAA receptor function in neuropathic pain" (Nature Communications, 2020) and "Treating pathological pain: Is KCC2 the key to the gate?" (2013), part of his 12 publications that have accumulated 541 citations. He contributes to academic governance as an ex officio member of the University of Otago Research Committee, a committee member for New Zealand and the Pacific Islands in the Australasian Research Management Society (ARMS), and a Governance Board Member at the Dodd-Walls Centre for Photonic Innovation.